Table 3.
Characteristic | Stressa | PTSDb,c | Depressiond | Anxietye | ||||||||
|
Mean (SD) | P value | Mean (SD) | P value | Mean (SD) | P value | Mean (SD) | P value | ||||
Regionf | ||||||||||||
|
New England | 18.31 (6.47) | .37 | 1.68 (0.89) | .82 | 8.92 (4.15) | .70 | 6.01 (3.75) | .36 | |||
|
Mid-Atlantic | 18.66 (6.46) | <.001 | 1.72 (0.91) | .62 | 9.13 (4.22) | .03 | 6.07 (3.81) | .07 | |||
|
East North Central | 17.75 (6.33) | .12 | 1.66 (0.90) | .56 | 8.81 (4.20) | .71 | 5.77 (3.62) | .40 | |||
|
West North Central | 17.92 (6.29) | .65 | 1.65 (0.87) | .56 | 8.86 (4.09) | .97 | 5.97 (3.82) | .51 | |||
|
South Atlantic | 17.81 (6.31) | .14 | 1.63 (0.87) | .06 | 8.51 (4.04) | <.001 | 5.73 (3.57) | .18 | |||
|
East South Central | 18.76 (6.87) | .14 | 1.67 (0.93) | .92 | 9.15 (4.43) | .34 | 5.92 (3.70) | .81 | |||
|
West South Central | 17.73 (6.43) | .24 | 1.62 (0.92) | .14 | 8.86 (4.24) | .96 | 5.67 (3.63) | .22 | |||
|
Mountain West | 18.03 (6.13) | .94 | 1.69 (0.86) | .56 | 8.94 (4.10) | .54 | 5.82 (3.47) | .73 | |||
|
Pacific West | 18.03 (6.14) | .88 | 1.70 (0.87) | .16 | 8.88 (4.06) | .79 | 5.88 (3.50) | .79 | |||
State COVID-19 prevalenceg | ||||||||||||
|
High-prevalence state | 18.23 (6.21) | .08 | 1.71 (0.86) | .004 | 8.89 (4.06) | .80 | 5.92 (3.60) | .20 | |||
|
Low-prevalence state | 17.97 (6.38) | N/Ah | 1.65 (0.89) | N/A | 8.86 (4.18) | N/A | 5.81 (3.64) | N/A | |||
Total, median (SD) | 18.08 (6.31) | N/A | 1.67 (0.89) | N/A | 8.72 (4.13) | N/A | 5.86 (3.62) | N/A |
aStress was measured using the total score on the Perceived Stress Scale.
bPTSD: posttraumatic stress disorder.
cPTSD was measured using mean scores on the Impact of Events Scale-6.
dDepression was measured using the Depression subscale score on the Hospital Depression and Anxiety Scale.
eAnxiety was measured using the Anxiety subscale score on the Hospital Depression and Anxiety Scale.
fStates within each region are based on US Census divisions.
gState-level COVID-19 prevalence is based on the number of COVID-19 cases per 100,000 at the time of the first survey distribution (April 22, 2020); high-prevalence states were California, Colorado, Illinois, Massachusetts, New Jersey, New York, and Washington.
hN/A: not applicable.